Cargando…

Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis

Objective To estimate the cumulative radiation exposure and lifetime attributable risk of cancer incidence associated with lung cancer screening using annual low dose computed tomography (CT). Design Secondary analysis of data from a lung cancer screening trial and risk-benefit analysis. Setting 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Rampinelli, Cristiano, De Marco, Paolo, Origgi, Daniela, Maisonneuve, Patrick, Casiraghi, Monica, Veronesi, Giulia, Spaggiari, Lorenzo, Bellomi, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421449/
https://www.ncbi.nlm.nih.gov/pubmed/28179230
http://dx.doi.org/10.1136/bmj.j347
_version_ 1783234586477592576
author Rampinelli, Cristiano
De Marco, Paolo
Origgi, Daniela
Maisonneuve, Patrick
Casiraghi, Monica
Veronesi, Giulia
Spaggiari, Lorenzo
Bellomi, Massimo
author_facet Rampinelli, Cristiano
De Marco, Paolo
Origgi, Daniela
Maisonneuve, Patrick
Casiraghi, Monica
Veronesi, Giulia
Spaggiari, Lorenzo
Bellomi, Massimo
author_sort Rampinelli, Cristiano
collection PubMed
description Objective To estimate the cumulative radiation exposure and lifetime attributable risk of cancer incidence associated with lung cancer screening using annual low dose computed tomography (CT). Design Secondary analysis of data from a lung cancer screening trial and risk-benefit analysis. Setting 10 year, non-randomised, single centre, low dose CT, lung cancer screening trial (COSMOS study) which took place in Milan, Italy in 2004-15 (enrolment in 2004-05). Secondary analysis took place in 2015-16. Participants High risk asymptomatic smokers aged 50 and older, who were current or former smokers (≥20 pack years), and had no history of cancer in the previous five years. Main outcome measures Cumulative radiation exposure from low dose CT and positron emission tomography (PET) CT scans, calculated by dosimetry software; and lifetime attributable risk of cancer incidence, calculated from the Biological Effects of Ionizing Radiation VII (BEIR VII) report. Results Over 10 years, 5203 participants (3439 men, 1764 women) underwent 42 228 low dose CT and 635 PET CT scans. The median cumulative effective dose at the 10th year of screening was 9.3 mSv for men and 13.0 mSv for women. According to participants’ age and sex, the lifetime attributable risk of lung cancer and major cancers after 10 years of CT screening ranged from 5.5 to 1.4 per 10 000 people screened, and from 8.1 to 2.6 per 10 000 people screened, respectively. In women aged 50-54, the lifetime attributable risk of lung cancer and major cancers was about fourfold and threefold higher than for men aged 65 and older, respectively. The numbers of lung cancer and major cancer cases induced by 10 years of screening in our cohort were 1.5 and 2.4, respectively, which corresponded to an additional risk of induced major cancers of 0.05% (2.4/5203). 259 lung cancers were diagnosed in 10 years of screening; one radiation induced major cancer would be expected for every 108 (259/2.4) lung cancers detected through screening. Conclusion Radiation exposure and cancer risk from low dose CT screening for lung cancer, even if non-negligible, can be considered acceptable in light of the substantial mortality reduction associated with screening.
format Online
Article
Text
id pubmed-5421449
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-54214492017-05-12 Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis Rampinelli, Cristiano De Marco, Paolo Origgi, Daniela Maisonneuve, Patrick Casiraghi, Monica Veronesi, Giulia Spaggiari, Lorenzo Bellomi, Massimo BMJ Research Objective To estimate the cumulative radiation exposure and lifetime attributable risk of cancer incidence associated with lung cancer screening using annual low dose computed tomography (CT). Design Secondary analysis of data from a lung cancer screening trial and risk-benefit analysis. Setting 10 year, non-randomised, single centre, low dose CT, lung cancer screening trial (COSMOS study) which took place in Milan, Italy in 2004-15 (enrolment in 2004-05). Secondary analysis took place in 2015-16. Participants High risk asymptomatic smokers aged 50 and older, who were current or former smokers (≥20 pack years), and had no history of cancer in the previous five years. Main outcome measures Cumulative radiation exposure from low dose CT and positron emission tomography (PET) CT scans, calculated by dosimetry software; and lifetime attributable risk of cancer incidence, calculated from the Biological Effects of Ionizing Radiation VII (BEIR VII) report. Results Over 10 years, 5203 participants (3439 men, 1764 women) underwent 42 228 low dose CT and 635 PET CT scans. The median cumulative effective dose at the 10th year of screening was 9.3 mSv for men and 13.0 mSv for women. According to participants’ age and sex, the lifetime attributable risk of lung cancer and major cancers after 10 years of CT screening ranged from 5.5 to 1.4 per 10 000 people screened, and from 8.1 to 2.6 per 10 000 people screened, respectively. In women aged 50-54, the lifetime attributable risk of lung cancer and major cancers was about fourfold and threefold higher than for men aged 65 and older, respectively. The numbers of lung cancer and major cancer cases induced by 10 years of screening in our cohort were 1.5 and 2.4, respectively, which corresponded to an additional risk of induced major cancers of 0.05% (2.4/5203). 259 lung cancers were diagnosed in 10 years of screening; one radiation induced major cancer would be expected for every 108 (259/2.4) lung cancers detected through screening. Conclusion Radiation exposure and cancer risk from low dose CT screening for lung cancer, even if non-negligible, can be considered acceptable in light of the substantial mortality reduction associated with screening. BMJ Publishing Group Ltd. 2017-02-08 /pmc/articles/PMC5421449/ /pubmed/28179230 http://dx.doi.org/10.1136/bmj.j347 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Rampinelli, Cristiano
De Marco, Paolo
Origgi, Daniela
Maisonneuve, Patrick
Casiraghi, Monica
Veronesi, Giulia
Spaggiari, Lorenzo
Bellomi, Massimo
Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
title Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
title_full Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
title_fullStr Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
title_full_unstemmed Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
title_short Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
title_sort exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421449/
https://www.ncbi.nlm.nih.gov/pubmed/28179230
http://dx.doi.org/10.1136/bmj.j347
work_keys_str_mv AT rampinellicristiano exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT demarcopaolo exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT origgidaniela exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT maisonneuvepatrick exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT casiraghimonica exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT veronesigiulia exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT spaggiarilorenzo exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis
AT bellomimassimo exposuretolowdosecomputedtomographyforlungcancerscreeningandriskofcancersecondaryanalysisoftrialdataandriskbenefitanalysis